Advertisement

Chronic Opioid Therapy Modifies QST Changes After Ketamine Infusion in Chronic Pain Patients

Published:August 09, 2017DOI:https://doi.org/10.1016/j.jpain.2017.07.008

      Highlights

      • Opioid-utilizing subjects had decreased in changes in temporal summation after a ketamine infusion.
      • Similar changes were not observed in non-opioid utilizing subjects.
      • Other QST parameters were not different following ketamine infusion when compared to placebo.
      • Subtle changes in altered QST profiles may suggest evidence of opioid-induced hyperalgesia.

      Abstract

      The long-term effects of opioids on sensitization processes are believed to be mediated through the N-methyl-D-aspartate receptor. Quantitative sensory testing (QST) changes observed after a ketamine infusion have been previously described but the effect that chronic opioids will have is not known. The results of this prospective randomized factorial trial compared the thermal QST changes observed after a .05 mg/kg ketamine infusion or a saline placebo in chronic pain subjects who were either opioid-naive or were chronically using opioids for chronic noncancer pain are presented. No baseline QST differences were noted between the 4 groups at baseline. Comparison of changes preinfusion with postinfusion QST measurements resulted in decreased average change in temporal summation response between opioid subjects who received a placebo compared with those who received a ketamine infusion (−5.22, SD = 9.96 vs 13.81, SD = 19.55; P = .004). Additionally, the average change in temporal summation was decreased among subjects who received a ketamine infusion and were not chronically using opioids compared with subjects who were using chronic opioids and received a placebo infusion (−1.91, SD = 13.25 vs 13.81, SD = 19.55; P = .007). The results indicate that low-dose ketamine infusions produce subtle changes in QST phenotypes that are modified by the chronic use of opioids. This illustrates the potential diagnostic and therapeutic value of ketamine in the setting of chronic opioid use.

      Perspective

      The presented data further our understanding of modulation of sensory perception in the setting of chronic opioid use and the role of the N-methyl-D-aspartate receptor. The use of low-dose ketamine infusions may be useful for the treatment as well as diagnosis of opioid-related neuropathic conditions.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benrath J.
        • Brechtel C.
        • Stark J.
        • Sandkuhler J.
        Low dose of S+-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo.
        Br J Anaesth. 2005; 95: 518-523
        • Bouhassira D.
        • Wilhelm S.
        • Schacht A.
        • Perrot S.
        • Kosek E.
        • Cruccu G.
        • Freynhagen R.
        • Tesfaye S.
        • Lledo A.
        • Choy E.
        • Marchettini P.
        • Mico J.A.
        • Spaeth M.
        • Skljarevski V.
        • Tolle T.
        Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study.
        Pain. 2014; 155: 2171-2179
        • Chen L.
        • Malarick C.
        • Seefeld L.
        • Wang S.
        • Houghton M.
        • Mao J.
        Altered quantitative sensory testing outcome in subjects with opioid therapy.
        Pain. 2009; 143: 65-70
        • Chen L.
        • Sein M.
        • Vo T.
        • Amhmed S.
        • Zhang Y.
        • Hilaire K.S.
        • Houghton M.
        • Mao J.
        Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia.
        J Opioid Manag. 2014; 10: 383-393
        • Chu L.F.
        • D’Arcy N.
        • Brady C.
        • Zamora A.K.
        • Young C.A.
        • Kim J.E.
        • Clemenson A.M.
        • Angst M.S.
        • Clark J.D.
        Analgesic tolerance without demonstrable opioid-induced hyperalgesia: A double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain.
        Pain. 2012; 153: 1583-1592
        • Dahan A.
        • Olofsen E.
        • Niesters M.
        Pharmacotherapy for pain: Efficacy and safety issues examined by subgroup analyses.
        Pain. 2015; 156: S119-S126
        • Eide P.K.
        • Jorum E.
        • Stubhaug A.
        • Bremnes J.
        • Breivik H.
        Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo.
        Pain. 1994; 58: 347-354
        • Eide P.K.
        • Stubhaug A.
        • Stenehjem A.E.
        Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation.
        Neurosurgery. 1995; 37: 1080-1087
        • Freeman R.
        • Baron R.
        • Bouhassira D.
        • Cabrera J.
        • Emir B.
        Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs.
        Pain. 2014; 155: 367-376
        • Ghelardini C.
        • Galeotti N.
        • Vivoli E.
        • Norcini M.
        • Zhu W.
        • Stefano G.B.
        • Guarna M.
        • Bianchi E.
        Molecular interaction in the mouse PAG between NMDA and opioid receptors in morphine-induced acute thermal nociception.
        J Neurochem. 2008; 105: 91-100
        • Graven-Nielsen T.
        • Aspegren Kendall S.
        • Henriksson K.G.
        • Bengtsson M.
        • Sorensen J.
        • Johnson A.
        • Gerdle B.
        • Arendt-Nielsen L.
        Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients.
        Pain. 2000; 85: 483-491
        • Lee J.H.
        • Cho S.H.
        • Kim S.H.
        • Chae W.S.
        • Jin H.C.
        • Lee J.S.
        • Kim Y.I.
        The effect of target-controlled infusion of low-dose ketamine on heat pain and temporal summation threshold.
        J Anesth. 2011; 25: 516-522
        • Leung A.
        • Wallace M.S.
        • Ridgeway B.
        • Yaksh T.
        Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain.
        Pain. 2001; 91: 177-187
        • Lilius T.O.
        • Jokinen V.
        • Neuvonen M.S.
        • Niemi M.
        • Kalso E.A.
        • Rauhala P.V.
        Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.
        Br J Pharmacol. 2015; 172: 2799-2813
        • Maher D.P.
        • Chen L.
        • Mao J.
        Intravenous ketamine infusions for neuropathic pain management: A promising therapy in need of optimization.
        Anesth Analg. 2017; 124: 661-674
        • Maher D.P.
        • Ding W.
        • Singh S.
        • Opalacz A.
        • Fishman C.
        • Houghton M.
        • Ahmed S.
        • Chen L.
        • Mao J.
        • Zhang Y.
        Thermal QST phenotypes associated with response to lumbar epidural steroid injections: A pilot study.
        Pain Med. 2017; 18: 1455-1463
        • Maier C.
        • Baron R.
        • Tolle T.R.
        • Binder A.
        • Birbaumer N.
        • Birklein F.
        • Gierthmuhlen J.
        • Flor H.
        • Geber C.
        • Huge V.
        • Krumova E.K.
        • Landwehrmeyer G.B.
        • Magerl W.
        • Maihofner C.
        • Richter H.
        • Rolke R.
        • Scherens A.
        • Schwarz A.
        • Sommer C.
        • Tronnier V.
        • Uceyler N.
        • Valet M.
        • Wasner G.
        • Treede R.D.
        Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes.
        Pain. 2010; 150: 439-450
        • Mao J.
        Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy.
        Pain. 2002; 100: 213-217
        • Mao J.
        • Mayer D.J.
        Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain.
        Ann N Y Acad Sci. 2001; 933: 175-184
        • Mao J.
        • Price D.D.
        • Mayer D.J.
        Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C.
        J Neurosci. 1994; 14: 2301-2312
        • Mao J.
        • Price D.D.
        • Mayer D.J.
        Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain.
        Pain. 1995; 61: 353-364
        • Mao J.
        • Sung B.
        • Ji R.R.
        • Lim G.
        Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity.
        J Neurosci. 2002; 22: 8312-8323
        • Mendez I.A.
        • Trujillo K.A.
        NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats.
        Psychopharmacology (Berl). 2008; 196: 497-509
        • Niesters M.
        • Khalili-Mahani N.
        • Martini C.
        • Aarts L.
        • van Gerven J.
        • van Buchem M.A.
        • Dahan A.
        • Rombouts S.
        Effect of subanesthetic ketamine on intrinsic functional brain connectivity: A placebo-controlled functional magnetic resonance imaging study in healthy male volunteers.
        Anesthesiology. 2012; 117: 868-877
        • Price D.D.
        • Mao J.
        • Frenk H.
        • Mayer D.J.
        The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man.
        Pain. 1994; 59: 165-174
        • Roeckel L.A.
        • Le Coz G.M.
        • Gaveriaux-Ruff C.
        • Simonin F.
        Opioid-induced hyperalgesia: Cellular and molecular mechanisms.
        Neuroscience. 2016; 338: 160-182
        • Schwartzman R.J.
        • Grothusen J.
        • Kiefer T.R.
        • Rohr P.
        Neuropathic central pain: Epidemiology, etiology, and treatment options.
        Arch Neurol. 2001; 58: 1547-1550
        • Sigtermans M.J.
        • van Hilten J.J.
        • Bauer M.C.
        • Arbous M.S.
        • Marinus J.
        • Sarton E.Y.
        • Dahan A.
        Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1.
        Pain. 2009; 145: 304-311
        • Suzan E.
        • Eisenberg E.
        • Treister R.
        • Haddad M.
        • Pud D.
        A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: Is hydromorphone therapy a double-edged sword?.
        Pain Phys. 2013; 16: 65-76
        • Zhang Y.
        • Ahmed S.
        • Vo T.
        • St Hilaire K.
        • Houghton M.
        • Cohen A.S.
        • Mao J.
        • Chen L.
        Increased pain sensitivity in chronic pain subjects on opioid therapy: A cross-sectional study using quantitative sensory testing.
        Pain Med. 2015; 16: 911-922
        • Zhao Y.L.
        • Chen S.R.
        • Chen H.
        • Pan H.L.
        Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: Implications for opioid hyperalgesia and tolerance.
        J Biol Chem. 2012; 287: 25073-25085